Daily Roundup

NHC.ASX SEQ.ASX CU6.ASX CGF.ASX SFG.ASX

New Hope Corporation Ltd Reports Solid Operational Performance Amid Challenging Market Conditions

New Hope Corporation Ltd (ASX: NHC) has released its half-year results for the 2026 financial year, highlighting a period of solid operational performance as the company continues to execute its organic growth plans.

Despite facing a period of recovery at the Bengalla Mine and a lower coal price environment, New Hope's low-cost assets and disciplined approach have enabled the board to declare a fully franked interim dividend of 10.0 cents per ordinary share.

The Group's saleable coal production increased by 0.4% to 5.5 million tonnes, as the New Acland Mine continued to ramp up production. Looking ahead, the company expects further production increases as Bengalla Mine returns to its 13.4 million tonne per annum ROM coal production rate and New Acland gains access to the Manning Vale West pit in the final quarter of 2026.

While statutory revenue decreased by 20.1% to $814.4 million, and net profit after tax fell 84.0% to $54.3 million, the company remains focused on maintaining its resilient, low-cost operations and executing its organic growth plans to continue delivering value to shareholders.

Sequoia Explores Strategic Options for Retail Licensee Services

Sequoia Financial Group Ltd (ASX: SEQ) has announced a strategic review of its retail licensee services, with a particular focus on its wholly owned subsidiary, InterPrac Financial Planning Pty Ltd.

The review follows earlier decisions by Macquarie Group and Netwealth Group Limited to review or reconsider their arrangements with certain Australian Financial Services Licence (AFSL) providers within the Sequoia group.

As part of the process, Sequoia is considering a range of strategic options for InterPrac, which may include continued operation under revised arrangements, the transition of authorised representatives to alternative licensing structures, or the potential sale of the InterPrac business or its shares. The company is currently engaged in advanced discussions with a third party regarding a possible transaction involving InterPrac.

Clarity Pharmaceuticals Presents Positive Co-PSMA Trial Data

Clarity Pharmaceuticals Ltd (ASX: CU6) has announced positive results from the Co-PSMA (NCT06907641) Investigator-Initiated Trial, which were presented at the European Association of Urology (EAU) Congress 2026 and accepted for publication in the European Urology journal.

The trial evaluated the performance of Clarity's 64Cu-SAR-bisPSMA diagnostic product in a head-to-head comparison to the standard-of-care 68Ga-PSMA-11 in 50 patients with biochemical recurrence of prostate cancer and low PSA levels. The results showed that 64Cu-SAR-bisPSMA demonstrated superior diagnostic performance, with a significantly higher mean lesion count, a greater total number of lesions identified, and a higher true positive rate compared to 68Ga-PSMA-11.

Clarity is focused on advancing its SAR-bisPSMA program, including the ongoing Phase III AMPLIFY and CLARIFY trials, to seek regulatory approval for 64Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence.

Challenger Revises Offer to Acquire Pepper Money

Challenger Limited (ASX: CGF) has submitted a revised non-binding, confidential proposal to acquire Pepper Money Limited (ASX: PPM). The revised offer price has been reduced from $2.60 per share to $2.25 per share, less the final 2025 dividend and any special dividend.

Challenger has stated that the revised proposal represents its best and final offer, in the absence of a superior proposal. The discussions remain incomplete, and there is no certainty that the revised proposal will eventuate in a transaction.

Seafarms Group Ltd Suspended from ASX Quotation

Seafarms Group Ltd (ASX: SFG) has been suspended from quotation on the Australian Securities Exchange (ASX) due to a breach of Listing Rule 12.2 on financial condition. The suspension was initially imposed after SFG failed to lodge its Half Year Report for the period ended 31 December 2025.

While SFG subsequently lodged the report, the ASX has determined that the company's financial condition is not adequate to warrant the continued quotation of its securities. The suspension will remain in place until SFG is able to demonstrate compliance with the Listing Rules and that it is appropriate for the company's securities to be reinstated to quotation.